Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study.

ABSTRACT:

Background

Camrelizumab plus apatinib have demonstrated robust antitumor activity and safety in patients with advanced cervical cancer (CLAP study; NCT03816553). We herein present the updated long-term results of the CLAP study and explore potential biomarkers for survival. The outcomes of patients who underwent immune checkpoint inhibitor (ICI) retreatment were also reported.

Methods

In this phase II trial, eligible patients received camrelizumab 200 mg intravenously every two weeks and apatinib 250 mg orally once daily in 4-week cycles for up to two years. Treatment was continued until disease progression, unacceptable toxicity, or withdrawal of consent.

Results

Between January 21 and August 1, 2019, a total of 45 patients were enrolled. Data were analyzed as of Jul

SUBMITTER: Lan C 

PROVIDER: S-EPMC11194449 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature